leadf
logo-loader
viewMedlab Clinical Ltd

Medlab Clinical receives first three batches of NanaBis™ from Tasmanian Alkaloids

TASALK is a world-leading fully integrated manufacturer and exporter of controlled substance extracts, including medicinal opiates and cannabis products.

Medlab Clinical Ltd - Medlab Clinical receives first three batches of NanaBis™ from Tasmanian Alkaloids
All NanaBis™ backorders have now been fulfilled

Medlab Clinical Ltd (ASX:MDC) has received the first shipment of NanaBis™, the company's patented cannabis-based medicine, from Tasmanian Alkaloids Pty Ltd (TASALK).

In line with a commercial agreement executed in January, NanaBis™ production and analytical services have been transferred to TASALK.

This allows for manufacturing to be ramped up, increases overall product quality and supports a stronger manufacturing compliance for the Australian Therapeutic Goods Administration, US Food and Drug Administration and the European Medicines Agency.

"Continues to grow"

Medlab chief executive officer Dr Sean Hall said: “With the recent launch of the Observational Study and successful completion of the Phase 2 Advanced Cancer Pain Trial at Royal North Shore Hospital, demand for NanaBis™ continues to grow.

“Being able to partner with TASALK is very exciting and allows Medlab to increase production capacities drastically over the short-term and therefore to meet increased demand.”

Increased demand

The company reported that March quarterly revenue was achieved for NanaBis™ with an increase of approximately 26% over the previous quarter and more than 2,000 bottles were dispensed.

This increase in demand, along with supply chain limitations during COVID-19, resulted in the need to ration stock and this saw the product being out of stock for the month of May.

All backorders have now been fulfilled.

Shares have been as much as 5% higher to 21.5 cents intra-day.

Quick facts: Medlab Clinical Ltd

Price: 0.18 AUD

ASX:MDC
Market: ASX
Market Cap: $50.34 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Medlab Clinical forges ahead in new vitamin trials for chronic illnesses

Medlab Clinical Ltd (ASX:MDC) chief executive officer Sean Hall tells Proactive Investors how the company is tapping into new areas of its “therapeutic toolkit” to better assist those with chronic health conditions.   Hall says there has been a shortfall in the standard of...

on 05/07/2019

2 min read